EA202193038A1 - Антитела против sema3a и их применения для лечения заболеваний глаз - Google Patents

Антитела против sema3a и их применения для лечения заболеваний глаз

Info

Publication number
EA202193038A1
EA202193038A1 EA202193038A EA202193038A EA202193038A1 EA 202193038 A1 EA202193038 A1 EA 202193038A1 EA 202193038 A EA202193038 A EA 202193038A EA 202193038 A EA202193038 A EA 202193038A EA 202193038 A1 EA202193038 A1 EA 202193038A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
antibodies against
eye diseases
sema3a
against sema3a
Prior art date
Application number
EA202193038A
Other languages
English (en)
Inventor
Лео Томас
Рэйчел Ребекка Барретт
Кристин Лора Боват
Раджкумар Ганешан
Приянка Гупта
Фэй Хань
Дунмэй Лю
Йюрген Престле
Санджая Сингх
Сатхьядеви Венкатарамани
Хелен Хайся У
Нина Циппель
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA202193038A1 publication Critical patent/EA202193038A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Настоящее изобретение относится к антителам и их фрагментам, нацеленным на семафорин 3A (Sema3A). Более конкретно, раскрыты антитела против Sema3A и способы применения для лечения различных заболеваний или расстройств.
EA202193038A 2019-05-09 2020-05-08 Антитела против sema3a и их применения для лечения заболеваний глаз EA202193038A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19173454 2019-05-09
PCT/EP2020/062802 WO2020225400A1 (en) 2019-05-09 2020-05-08 Anti-sema3a antibodies and their uses for treating eye or ocular diseases

Publications (1)

Publication Number Publication Date
EA202193038A1 true EA202193038A1 (ru) 2022-03-30

Family

ID=66476463

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202193038A EA202193038A1 (ru) 2019-05-09 2020-05-08 Антитела против sema3a и их применения для лечения заболеваний глаз

Country Status (22)

Country Link
US (2) US11267880B2 (ru)
EP (1) EP3966239A1 (ru)
JP (2) JP7314310B2 (ru)
KR (1) KR20220007128A (ru)
CN (1) CN113795509A (ru)
AR (1) AR122266A1 (ru)
AU (1) AU2020267874A1 (ru)
BR (1) BR112021019854A2 (ru)
CA (1) CA3137377A1 (ru)
CL (1) CL2021002795A1 (ru)
CO (1) CO2021014768A2 (ru)
CR (1) CR20210559A (ru)
DO (1) DOP2021000226A (ru)
EA (1) EA202193038A1 (ru)
EC (1) ECSP21082527A (ru)
IL (1) IL287758A (ru)
JO (1) JOP20210300A1 (ru)
MA (1) MA55872A (ru)
MX (1) MX2021013671A (ru)
PE (1) PE20220287A1 (ru)
SG (1) SG11202110842QA (ru)
WO (1) WO2020225400A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11267880B2 (en) 2019-05-09 2022-03-08 Boehringer Ingelheim International Gmbh Anti-Sema3A antibodies and their uses for treating eye or ocular diseases
US20220127344A1 (en) * 2020-10-23 2022-04-28 Boehringer Ingelheim International Gmbh Anti-sema3a antibodies and their uses for treating a thrombotic disease of the retina
CN117396504A (zh) * 2021-03-30 2024-01-12 拜耳公司 抗Sema3A抗体及其用途
CN116790610A (zh) * 2023-05-18 2023-09-22 四川大学 一种治疗骨科疾病的基因及以aav为载体的基因治疗药物

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
DK0669836T3 (da) 1992-11-13 1996-10-14 Idec Pharma Corp Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
JP5888728B2 (ja) 2009-11-05 2016-03-22 国立大学法人大阪大学 自己免疫疾患又はアレルギー治療剤とそのスクリーニング方法
WO2013005603A1 (ja) 2011-07-01 2013-01-10 公立大学法人横浜市立大学 結膜におけるアレルギー性炎症の予防及び／又は治療剤
JP6372040B2 (ja) 2013-02-06 2018-08-15 公立大学法人横浜市立大学 抗セマフォリン３ａ抗体、並びにこれを用いたアルツハイマー病及び免疫・炎症性疾患の治療
WO2014127479A1 (en) 2013-02-21 2014-08-28 Rsem, Limited Partnership Inhibition of sema3a in the prevention and treatment of ocular hyperpermeability
LT3189074T (lt) 2014-09-05 2021-06-10 Rsem, Limited Partnership Kompozicijos ir būdai skirti uždegimo gydymui ir prevencijai
CN108290942B (zh) 2015-10-27 2021-08-27 社会福祉法人三星生命公益财团 与人及小鼠信号素3a交联的抗体及其用途
KR101854529B1 (ko) 2015-10-27 2018-05-04 (주) 팬젠 인간 및 마우스 Ｓｅｍａ３Ａ에 교차결합하는 항체 및 그의 용도
US10604571B2 (en) 2015-10-27 2020-03-31 Samsung Life Public Welfare Foundation Antibody to human and mouse SEMA3A and use thereof
US11267880B2 (en) 2019-05-09 2022-03-08 Boehringer Ingelheim International Gmbh Anti-Sema3A antibodies and their uses for treating eye or ocular diseases

Also Published As

Publication number Publication date
CR20210559A (es) 2021-12-23
JP7314310B2 (ja) 2023-07-25
CL2021002795A1 (es) 2022-08-05
JOP20210300A1 (ar) 2023-01-30
US20200385446A1 (en) 2020-12-10
JP2023130473A (ja) 2023-09-20
WO2020225400A1 (en) 2020-11-12
US11267880B2 (en) 2022-03-08
MA55872A (fr) 2022-03-16
AR122266A1 (es) 2022-08-31
MX2021013671A (es) 2021-12-10
KR20220007128A (ko) 2022-01-18
CO2021014768A2 (es) 2021-11-19
PE20220287A1 (es) 2022-02-25
US20220144929A1 (en) 2022-05-12
IL287758A (en) 2022-01-01
BR112021019854A2 (pt) 2022-02-15
AU2020267874A1 (en) 2021-10-28
SG11202110842QA (en) 2021-10-28
EP3966239A1 (en) 2022-03-16
JP2022531698A (ja) 2022-07-08
CN113795509A (zh) 2021-12-14
CA3137377A1 (en) 2020-11-12
DOP2021000226A (ru) 2021-12-15
TW202108621A (zh) 2021-03-01
ECSP21082527A (es) 2021-12-30

Similar Documents

Publication Publication Date Title
EA202193038A1 (ru) Антитела против sema3a и их применения для лечения заболеваний глаз
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA201990912A1 (ru) Анти-lag-3 антитела и их композиции
CY1123781T1 (el) Anti-tnf αλφα-αντισωματα και λειτουργικα θραυσματα αυτων
EA202091482A1 (ru) Антитела
EA201792561A1 (ru) Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения
EA202190138A1 (ru) Анти-sirp-бета1 антитела и способы их использования
MX2020008122A (es) Anticuerpos anti-pd-1.
EA202191764A1 (ru) Замещенные оксопиридиновые производные
EA202090401A1 (ru) Анти-tim-3 антитела и их применение
EA202190807A1 (ru) Антитела к синуклеину
EA202190647A1 (ru) Антитела к klrg1
EA202091478A1 (ru) Антитела
EA201992626A1 (ru) Способы и композиции для лечения аллергических заболеваний глаз
EA202092593A1 (ru) Белки, связывающие каннабиноидный рецептор 1-го типа (cb1), и их применение
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
EA202192488A1 (ru) Антитела против tsg-6 и их применения
EA202191758A1 (ru) Пептиды для лечения и профилактики диабета и связанных с ним заболеваний
MX2020013243A (es) Anticuerpos anti-il-22, fragmentos de anticuerpo, sus inmunoconjugados y usos de los mismos.
EA201991395A1 (ru) Новые композиции для лечения суставных нарушений
CR20220122A (es) Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares
EA201990493A1 (ru) Антитела к гм-ксф и их применения
MX2023004643A (es) Anticuerpos anti-sema3a y sus usos para tratar una enfermedad trombotica de la retina.
EA202090145A1 (ru) Тканевые филлеры на основе шелка и гиалуроновой кислоты и способы их применения
EA202092121A1 (ru) Антитела против cd73 и их применения